This inventor holds 1 USPTO granted patent. Top assignee: Yonsei University. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Jonghyuk Sung: Innovator in Pharmaceutical Chemistry
Introduction
Jonghyuk Sung is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that may aid in the treatment of cystic fibrosis.
Latest Patents
Jonghyuk Sung holds a patent for "Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredient." This patent describes an indolizino[3,2-c]quinoline derivative and its pharmaceutically acceptable salt, which may function as an agonist of the cystic fibrosis conductance transmembrane regulator. This innovation could be instrumental in preventing or treating diseases caused by the degradation of this regulator's activity and may also stimulate the proliferation of stem cells.
Career Highlights
Jonghyuk Sung is affiliated with Yonsei University, where he continues to engage in research and development in the pharmaceutical field. His work is characterized by a commitment to advancing medical science and improving treatment options for patients.
Collaborations
He collaborates with esteemed colleagues, including Ikyon Kim and Wan Namkung, who contribute to his research endeavors and enhance the impact of his innovations.
Conclusion
Jonghyuk Sung's contributions to pharmaceutical chemistry, particularly through his patented innovations, highlight his role as a key figure in the fight against cystic fibrosis. His work not only advances scientific knowledge but also holds promise for improving patient outcomes.